What Researchers Did
Researchers conducted a systematic review of six animal studies testing whether HBOT (typically 2.0–2.2 ATA, 85–100% oxygen, 40–60 minutes per session) can improve bone density and bone structure in rats with osteoporosis caused by ovariectomy, immobilization, spinal cord injury, or aging.
What They Found
Across all six studies, HBOT improved bone mineral density, trabecular bone thickness, and bone strength compared to untreated controls. HBOT increased markers of new bone formation (including osteocalcin and bone-specific alkaline phosphatase) and reduced markers of bone breakdown (such as C-terminal telopeptide and TRAP-5b). The mechanisms involve the OPG/RANKL bone remodeling axis, Wnt/β-catenin signaling, reduced inflammation, and improved blood vessel growth to bone.
What This Means for Canadian Patients
Osteoporosis affects an estimated 2 million Canadians and is a leading cause of fractures and reduced quality of life, especially in older women. This systematic review shows HBOT may directly build bone, not just as a side effect, but as a primary mechanism, through multiple biological pathways. While human trials are still needed, this is encouraging for Canadians who cannot tolerate or do not respond fully to standard osteoporosis medications.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
All six studies were conducted in rats, used varied HBOT protocols, and had mixed risk-of-bias ratings; no human clinical trials on HBOT for osteoporosis have been conducted, so these findings cannot yet be applied to patient care.